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Non-alcoholic fatty liver disease is the most common liver disease worldwide. Here, 
we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver 
disease. Reduced Mfn2 expression was detected in liver biopsies from patients with 
non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2 expression was 
detected in mouse models of steatosis or NASH, and its re-expression in a NASH 
mouse model ameliorated the disease. Liver-specific ablation of Mfn2 in mice 
provoked inflammation, triglyceride accumulation, fibrosis and liver cancer. We 
demonstrate that Mfn2 binds phosphatidylserine (PS) and can specifically extract 
PS into membrane domains, favoring PS transfer to mitochondria, as well as 
mitochondrial phosphatidylethanolamine (PE) synthesis. Consequently, hepatic 
Mfn2 deficiency reduces PS transfer and phospholipid synthesis, leading to 
endoplasmic reticulum (ER) stress and the development of a NASH-like phenotype 
and liver cancer. Thus, ablation of Mfn2 in liver reveals that disruption of ER-
mitochondrial PS transfer is a new mechanism involved in the development of liver 





Non-alcoholic fatty liver disease (NAFLD) is among the most common liver diseases 
worldwide, with increasing prevalence in parallel with the obesity/metabolic syndrome 
epidemic. NAFLD represents a clinical spectrum ranging from simple steatosis and 
non-alcoholic steatohepatitis (NASH) to cirrhosis and hepatocellular carcinoma (HCC)1. 
NASH is accompanied by inflammation, cell death, and fibrosis, and is characterized 
histologically by the presence of ballooning hepatocytes and lobular inflammation with 
or without perisinusoidal fibrosis and steatosis2. Hepatic inflammation is a complex 
process that originates in response to a variety of stress conditions3. In the course of the 
inflammatory process, liver hepatocytes frequently die by programmed cell death. The 
persistent cycle of “necro-inflammation” and hepatocyte regeneration is believed to 
enhance the risk of genetic mutation in hepatocytes, promoting survival and expansion 
of initiated cells. The result is increased cell growth, also referred to as compensatory 
proliferation, which can lead to tumor development4,5. In this context, epidemiological 
and clinical studies have provided convincing evidence that chronic inflammation leads 
to carcinogenesis6-9. 
Several potential factors influencing NASH progression are known to interact10-15, such 
as hepatic endoplasmic reticulum (ER) stress, oxidative stress, mitochondrial 
dysfunction and lipotoxicity. Mitochondrial function is governed by the preservation of 
a normal lipid composition16-19, which is dependent on the capacity of mitochondria to 
synthesize phospholipids, and by the traffic of lipids from the ER to mitochondria20-22. 
Specifically, phosphatidylserine (PS) is primarily synthesized in the ER and is imported 
into mitochondria by transient membrane contact between mitochondria-associated ER 
membranes (MAMs) and the mitochondrial outer membrane23. In mitochondria, PS is 
converted into phosphatidylethanolamine (PE), which is then  imported into the ER for 
conversion to phosphatidylcholine (PC)16,21,24,25. Accordingly, MAMs are key sites for 
synthesis and traffic of phospholipids17,25.  
Mitofusin 2 (Mfn2) is a mitochondrial membrane protein with a role connecting ER 
membranes to mitochondria26-28, and its depletion causes ER stress29-31. Mfn2 plays a 
relevant role in the maintenance of mitochondrial metabolism, insulin signaling and 
energy homeostasis30-33. Cancer cells of different origin show a low expression of Mfn2 
34-37. In addition, Mfn2 levels are significantly downregulated in HCC tissue compared 
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with corresponding adjacent normal tissue, and there is a negative correlation between 
Mfn2 levels and the prognosis of cancer38-40. Mfn2 overexpression in hepatocellular 
carcinoma or colorectal cancer cells  reduces cell proliferation and induces spontaneous 
apoptosis35,37. However, it is unknown whether Mfn2 downregulation is a cause or a 
consequence of cancer, and in addition, there are no data linking Mfn2 to NALFD 
progression.  
Here we show that hepatic Mfn2 is downregulated both in patients with NASH, and in 
subjects borderline for NASH. Further, mouse models of hepatic lipid accumulation or 
NASH present lower levels of Mfn2 in liver, and the re-expression of Mfn2 in liver 
ameliorates the NASH phenotype. We also demonstrate that hepatic Mfn2 ablation 
causes a NASH-like phenotype that progresses to liver cancer with age. We show that 
Mfn2 binds to and participates in the transfer of PS. Accordingly, hepatic Mfn2 
deficiency causes a reduced transfer of PS from ER to mitochondria, which leads to 
reduced PS synthesis and ER stress, in turn causing inflammation, fibrosis and liver 
cancer. Overall, our data strongly suggest that Mfn2 constitutes a new target for the 




Human liver samples of non-alcoholic steatohepatitis present low levels of Mfn2  
To investigate whether Mfn2 is dysregulated in NASH, we compared its expression in 
liver biopsies from patients with steatosis or NASH. Clinical, anthropometric, and 
biochemical data of this cohort have been reported previously41. Results showed that 
protein levels of Mfn2 were significantly lower in liver from patients with NASH than 
in subjects with simple steatosis (Figure 1A). We also analyzed human liver biopsies 
from a second cohort of subjects without NASH (NAS index <3) and close to borderline 
NASH (NAS index ≥5). NAS scoring was performed according Takeda et al.,42. 
Clinical characteristics of these patients are shown in Supplementary Table 1. Both 
Mfn2 mRNA and protein levels were significantly decreased in patients with borderline 
NASH (Figures S1A, S1B and S1C). By contrast, expression of the Mfn2 homologue 
Mfn1 was unaltered in this group (Figure S1D). Overall, these data show that Mfn2 is 
down-regulated in human liver during progression from steatosis to NASH.  
 
Mouse models of non-alcoholic liver disease have low hepatic levels of Mfn2 
To document the possible involvement of Mfn2 in NALFD, we studied its expression in 
C57BL6/J mice with steatosis induced by high-fat diet (HFD) over three weeks, a time 
sufficient to trigger hepatic steatosis43. Mfn2 protein expression in liver was significanly 
lower in the HFD group than in the control group (Figures 1B, and S1E). Because mice 
on HFD show fatty liver and obesity but not fibrosis44, we utilized a well-established 
mouse model of NASH consisting of a methionine/choline-deficient diet combined with 
45% HFD and supplemented with 0.1% L-methionine in drinking water, to avoid 
weight loss44 (hereafter termed MCD). C57BL6/J mice on MCD diet for 3 weeks 
showed substantial fat accumulation and liver fibrosis (detected by H&E and Sirius Red 
staining, respectively) (Figure 1C). Further, liver triglyceride levels and mRNA levels 
of inflammatory markers and the fibrotic marker TGF were significantly higher in 
mice on MCD diet than on control diet (Figures 1D, S1F and S1G). Under these 
conditions Mfn2 levels were diminished (Figures 1E, and S1H), and this decrease was 
greater in mice on MCD diet than on HFD (Figure 1B and 1E). Consistent with the data 
in human biopsies, Mfn1 protein levels were unaltered in mice on MCD diet (Figure 
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S1I). These results are consistent with a specific progressive repression of Mfn2 in 
mouse liver disease. 
 
Mfn2 ablation causes chronic hepatic inflammation and abnormal lipid metabolism 
To substantiate the role of Mfn2 in liver as a trigger of the NASH-like phenotype, we 
analyzed liver-specific Mfn2 knockout mice (L-KO) generated in our laboratory31. 
Under normal chow diet, 8 week-old L-KO mice showed a significant increase in the 
abundance of hepatic and plasma pro-inflammatory cytokines (Figures 1F, S2A and 
S2B), expression of hepatic pro-inflammatory genes (Figure S2C) and a modest but 
significant accumulation of triglycerides (Figure 1G). This occurred in the absence of 
changes in body weight, food intake or circulating lipids (Figures S2D–H). Further 
analysis of lipid metabolism in hepatocytes isolated from L-KO and control mice 
revealed that the esterification of oleate into diacylglycerol and triacylglycerol was 
enhanced in the former, but their incorporation into phospholipids was decreased 
(Figure 1H). Under these conditions, oleate -oxidation was decreased in Mfn2-
deficient hepatocytes (Figure S2I). Further, the expression of de novo lipogenesis and 
esterification genes was modestly elevated in liver from L-KO mice (Figures S2J). In 
sum, L-KO mice show a pattern typical of disturbances in hepatic lipid metabolism. 
 
Mfn2 ablation causes apoptosis, increased cell growth, fibrosis and liver cancer 
It is known that chronic hepatic inflammation is associated with enhanced apoptosis, 
leading to compensatory cell proliferation and fibrosis, which are known risk factors for 
liver cancer45,46. Given the chronic inflammation detected in L-KO mice, we analyzed 
the development of these processes to determine whether Mfn2 deficiency leads to liver 
cancer progression. Under normal conditions, apoptosis was higher in liver from L-KO 
mice than from controls, as demonstrated by increased levels of cleaved PARP-1 and 
cleaved caspase-3 (Figures S3A and S3B), and was accompanied by a higher number of 
Ki67-positive cells (Figure S3C), indicating enhanced proliferation. Furthermore,  the 
expression of genes encoding fibrotic markers was also elevated in L-KO livers (Figure 
1J), and Sirius red staining and transmission electron microscopy revealed a marked 
accumulation of extracellular collagen in livers at 27 weeks of age (Figure 1I).  
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We next explored whether hepatic Mfn2 deficiency promotes liver cancer as a 
consequence of the natural progression of liver disease. Accordingly, L-KO and control 
mice on normal diet were examined for liver tumors at twenty-four months of age. 
Analysis showed that the number of tumors was significantly higher in L-KO mice than 
in control mice, and tumor volume was also greater (Figures 1K and S3D). We next 
sought to validate these results by investigating whether L-KO mice showed a 
differential predisposition to the liver-specific carcinogen diethylnitrosamine (DEN). 
Treatment of mice with DEN triggers a well-known cascade of events in liver that 
include DNA damage and apoptosis of centrilobular hepatocytes, production of 
proinflammatory cytokines and compensatory proliferation47. As a first approach, we 
induced liver DNA damage with a single high-dose intraperitoneal injection of DEN (50 
mg/kg) to assess the acute liver response. Immunohistological examination of livers 48 
h after DEN injection revealed a stronger DNA damage response in centrilobular 
regions in L-KO mice than in controls, and this accompanied by greater levels of 
compensatory proliferation (Figures S3E, S3F, and S3G). We next treated control and 
L-KO mice with a single lower dose of DEN (5 mg/kg), followed by continued 
exposure to HFD. After seven months L-KO mice subjected to DEN-HFD treatment 
showed a larger number of tumors and greater tumor size compared to control treated 
mice (Figure S3H). Thus, our data indicate that hepatic Mfn2 ablation leads to 
apoptosis, increased cell proliferation, fibrosis, and a greater susceptibility to develop 
liver cancer.  
 
Mfn2 re-expression restores normal liver metabolism in L-KO mice 
To assess whether the alterations detected in Mfn2-deficient livers were attributable to 
Mfn2 loss-of-function or to compensatory mechanisms, we re-expressed Mfn2 in L-KO 
mice by intravenous administration of adenoviruses encoding either Mfn2 or LacZ 
(AdC, used as a control). Upon Mfn2 re-expression (Figure S4A) hepatic and plasma 
cytokines returned to control levels (Figures S4B–D) and the expression of fibrosis 
genes and pro-inflammatory genes were markedly down-regulated (Figure S4E and 
S4G). Moreover, triacylglycerol levels were normalized (Figure S4F), and oleate -
oxidation was enhanced (Figure S4H).  
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We have previously reported that under normal chow diet, 8-week-old L-KO mice 
present an elevated unfolded protein response (UPR)31. Thus, we surveyed the impact of 
Mfn2 re-expression on ER stress markers. Results showed that Mfn2 re-expression 
normalized  the different UPR parameters (Figure S4I). These data strongly suggest that 
Mfn2 is directly responsible for the liver abnormalities found in L-KO mice. 
 
Normalization of ER stress triggered by Mfn2 deficiency ameliorates inflammation and 
fibrosis but not the impaired lipid metabolism 
The up-regulation of UPR proteins, such as CHOP, is sufficient to promote liver 
apoptosis, inflammation, compensatory proliferation, fibrosis and liver cancer48. To 
begin to elucidate the mechanisms by which Mfn2 deficiency triggers the development 
of cancer, we examined the contribution of ER stress to these processes in the L-KO 
model. We blocked ER stress by overexpressing a critical regulator of UPR signaling, 
BIP (GRP-78). Because hepatic BIP gain-of-function in control mice has been shown to 
cause hypoglycemia and sudden death, even upon administration of very low levels of 
adenovirus, in models that do not present UPR activation (data not shown and previous 
reports49,50), we expressed BIP by adenoviral intravenous injection only in L-KO mice, 
which show chronic ER stress.    
Acute BIP overexpression decreased UPR signaling in L-KO mice (Figure 2A, and 
S5A). Moreover, liver and plasma circulating pro-inflammatory cytokines were 
normalized by BIP (Figure 2B, and 2C), and the expression of genes encoding pro-
inflammatory or fibrotic factors was also markedly lower than that seen in equivalent 
controls (Figure 2D and S5B). Similarly, apoptosis and cell proliferation were decreased 
in L-KO mice expressing BIP (Figure S5C–D). In the context of mitochondrial 
metabolism, BIP expression enhanced oleate oxidation (Figure S5E) and reduced ROS 
production measured as hydrogen peroxide (Figure S5F), thereby recovering 
mitochondrial function, which is in keeping with our previous data29. Intriguingly, BIP 
overexpression failed to restore hepatic triglyceride levels (Figure 2E) or the 
incorporation of oleate into lipids (Figure 2F). These data indicate that the hepatic 
mitochondrial dysfunction, inflammation, fibrosis, apoptosis and increased proliferation 




Mfn2 plays a crucial role in hepatic phospholipid metabolism 
It has been reported that an aberrant phospholipid composition of the ER membrane is a 
potent activator of the UPR51-53. Accordingly, we studied the total hepatic phospholipid 
content in L-KO mice in an attempt to identify mechanisms linking Mfn2 deficiency 
and UPR. Results from lipidomics analysis showed that L-KO mice had a decreased 
abundance of total hepatic PE and PC species (Figure 3A; statistical significance of the 
data is shown in Supplementary Table 2). Consistent with these data, the lipidomics 
profile of hepatic MAMs and mitochondrial fractions from L-KO and control mice was 
different (Figures S6A, and S6D), with a decrease in the abundance of PE and PC 
species in the former (Figures S6B, S6C, S6E, and SEF; Supplementary Table 3). 
Because Mfn2 and some proteins of hepatic phospholipid synthesis are localized in 
mitochondria-ER contact sites (schematic shown in Figure 3B)26,29,54,55, we monitored 
the incorporation of radiolabeled L-serine (L-Ser) into PS, PE, and PC in hepatic MAM 
fractions from control and L-KO mice. We found that this incorporation was 
significantly decreased in MAM fractions from L-KO mice (Figure 3C–E).  
We next questioned whether ER stress plays a role in the defects detected in 
phospholipid synthesis by analyzing BIP-expressing L-KO mice. BIP expression failed 
to improve the incorporation of L-Ser into PS, PE or PC (Figure 3F); however, re-
expression of Mfn2 completely rescued L-Ser incorporation into phospholipids (Figure 
3G). Overall, our data indicate that hepatic Mfn2 depletion alters phospholipid synthesis 
and that these effects are not a consequence of ER stress. 
Phospholipid metabolism in mammalian cells depends on the activity of many enzymes 
including phosphatidylserine synthase 1 (PSS1), phosphatidylserine synthase 2 (PSS2), 
and PE N-methyltransferase (PEMT), which are localized in MAMs and the ER; and PS 
decarboxylase (PISD), which is found in mitochondria20,21. We therefore analyzed 
whether loss of Mfn2 altered the expression of these proteins. Analysis by western 
blotting showed that the hepatic expression of PSS1 and PSS2 proteins was 
significantly lower in L-KO mice than in control mice (Figure 3H), whereas no changes 
were observed for PEMT (Figure S6G) or PISD (data not shown).  
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We next assessed the protein composition in MAMs by examining the abundance of 
MAM-enriched proteins in liver upon subcellular fractionation (Figure 3I and S6H). 
Western blotting of hepatic MAM fractions revealed a 50% reduction in PSS1 
expression in L-KO mice (Figure 3I), whereas no changes were found for PSS2 whose 
expression was barely detectable (Figure 3I, and Figure S6I). Moreover, levels of 
PACS-2, Sig1R, and calnexin were elevated in MAMs from L-KO mice (Figures 3I, 
S6H, and S6I), which resembles the alterations in MAM composition in models of 
insulin resistance and aberrant lipid metabolism52,56. Thus, our results suggest that Mfn2 
regulates phospholipid biosynthesis through PSS1 and PSS2 protein levels.   
 
Alterations of lipid metabolism in L-KO mice are independent of the distance between 
ER and mitochondria 
Given the role of Mfn2 in tethering ER to mitochondria 26-28, we explored whether the 
distance between mitochondria and ER might regulate phospholipid synthesis in Mfn2-
ablated conditions. To do this, we used a recombinant adenovirus construct encoding a 
synthetic linker (RFP-linker) that increases the number ER-mitochondria contact sites, 
thus forcing ER-mitochondria interactions in L-KO mice (Figure S7A). Western blot 
analysis of RFP expression confirmed the expression of the linker (Figure S7A). L-KO 
mice expressing this linker showed a normalization of L-Ser incorporation into PS 
(Figure S7B); however, it failed to correct the synthesis of PE or PC, hepatic 
triacylglyceride levels, ER stress or PSS1 expression (Figures S7B–S7F). Under these 
conditions, PSS2 abundance was actually enhanced in L-KO mice (Figure S7F), which 
may explain the normalization of PS synthesis (Figure S7B). These results indicate that 
altered ER-mitochondria contact does not explain the lower synthesis of PE and PC in 
MAMs of Mfn2-deficient livers. 
 
Down-regulation of hepatic PSS1/2 phenocopies Mfn2 ablation 
In light of the above findings, we hypothesized that a decrease in phospholipid synthesis 
in MAMs causes hepatic triglyceride accumulation and ER stress in liver. To test this, 
we induced downregulation of either PSS1 or PSS2 in wild-type mice. Silencing of 
PSS1 by intravenous injection of a specific shRNA adenovirus caused the upregulation 
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of hepatic PSS2 and vice versa (Figure S8A,B), observations that are in agreement with 
previous data57-61. On the basis of these findings, which point to a strong adaptation 
process, we silenced both PSS1 and PSS2 in wild-type mice using two specific shRNA 
adenoviruses, which decreased the hepatic expression of both proteins by ~90% (Figure 
4A and S8C). Analysis of hepatic MAM fractions showed a significant decrease of 
PSS1 in PSS1/2 knockdown (hereafter termed KD) mice (Figure 4B). This resulted in a 
decrease in the incorporation of L-Ser into PS and PE (Figure 4C) and an increase in 
hepatic triacylglycerol and oleate incorporation into lipids (Figure 4D and S8D). KD 
mice also showed ER stress (Figure 4E and S8E), and a higher expression of the fibrosis 
gene -SMA and pro-inflammatory genes in liver (Figure 4F and S8F). In keeping with 
these observations, levels of hepatic pro-inflammatory cytokines were elevated in KD 
livers (Figure S8G); however, mitochondrial function (oleate oxidation or liver 
hydrogen peroxide production) was unaltered (Figure S8H and S8I).  
 
Analysis of MAM protein composition revealed alterations in response to hepatic 
PSS1/2 silencing, with a significant decrease of Mfn2 expression in KD mice (Figure 
4G). Also, PACS-2, Sig1R, and calnexin proteins were more abundant in MAMs from 
KD mice (Figures S8J–S8L), thus mirroring the alterations in MAM composition in 
Mfn2 L-KO mice. Overall, these results indicate that hepatic PSS1/2 deficiency 
recapitulates many of the hepatic alterations caused by Mfn2 ablation.  
We next attempted to counter the liver alterations in L-KO mice by overexpressing 
PSS1 (Figure 4H). PSS1 overexpression led to an upregulation of Ptdss2 mRNA in L-
KO mice (Figure 4I). As expected, we also found an increase in the synthesis of PS 
(Figure 4J), and surprisingly the normalization of liver triglycerides (Figure 4K). By 
contrast, PSS1 overexpression failed to rescue the synthesis of PE or PC (Figure 4J), or 
ameliorate the UPR (Figure 4L and S8M). Taken together, our data show that Mfn2 
depletion causes a fundamental defect that prevents the synthesis of PE from PS.  
 
Mfn2 is a PS-binding protein and generates PS-rich domains in membranes  
A key process in the synthesis of phospholipids in MAMs is the transfer of PS and PE 
between the ER and mitochondria20,22,25. To determine whether Mfn2 was involved in 
PS transfer, we first investigated whether it binds phospholipids by assaying binding of 
13 
 
immunoprecipitated Mfn2 to lipid strips. Mfn2 was specifically immunoprecipitated 
under denaturing immunoprecipitation conditions with a polyclonal antibody. Mfn2 
specifically bound phosphatidate (PA) and PS but not phosphatidylinositol (PI), PE or 
PC (Figure 5A). To validate this binding to phospholipids and to exclude the possibility 
that it was due to transmembrane domains, we constructed a truncated version of Mfn2 
lacking the transmembrane domains and the C-terminal cytosolic portion (1–613), but 
preserving some metabolic characteristics of the full-length protein62.  L-KO mice were 
tail vein injected with an adenoviral vector permitting the hepatic expression of this 
short form containing a 6×His tag at the N-terminus. We then purified the recombinant 
Mfn2 protein under denaturing conditions by affinity chromatography. Results showed 
that Mfn2 (1–613) could also specifically bind PS and PA (Figures 5B). To determine 
its potential in vivo role on phospholipid synthesis, we analyzed the effects on 
phospholipid synthesis by monitoring the incorporation of labeled L-Ser in the same L-
KO mice. Data revealed that Mfn2 (1–613) enhanced the incorporation of L-Ser into 
PS, PE and PC (Figure 5C).  
 
For in vitro analysis, we expressed Mfn2 (1–613) in E. coli and purified the protein by 
affinity chromatography that, after elution, represented >60% of the Comassie blue-
stained proteins in gel electrophoresis (Figure 5D). Eluted Mfn2 (1–613) was also 
identified by mass spectrometry and contaminants were detected at very low levels 
(Supplementary Table 4). When we analyzed the capacity of the recombinant protein to 
bind phospholipids, we observed specific binding to PS and to PA in lipid strip assays 
(Figures 5E), consistent with the results in the liver. To exclude false positive binding 
due to phospholipid positioning in the strip, we performed liposome flotation assays, 
which confirmed that Mfn2 (1–613) mainly bound PS conjugated to a fluorophore 
(NBD) and also natural PS (Figures 5F and S9A) in liposomes. Overall, these data 
indicate that Mfn2 shows a capacity to selectively bind PS with minimal binding to 
natural PA and PI.  
We next determined whether Mfn2 participates in the transfer of PS between 
membranes. We first evaluated its capacity to extract PS from liposomes, which may 
account for the alterations in the synthesis of PE in L-KO liver, even upon PSS1 
overexpression. Phospholipid extraction was performed as described by Kawano et al63.  
Purified Mfn2 (1–613) was incubated with liposomes containing labeled phospholipids 
14 
 
(NBD-PS or NBD-PE) and the mixture was then separated by gradient centrifugation 
(Figure 5G). Subsequently, we analyzed the liposome-containing fraction and the non-
liposome-containing fraction. Analysis of the distribution of NBD fluorescence in the 
presence of Mfn2 revealed that the fluorescence of NBD-PS decreased in the liposome 
fraction and increased in the non-liposome fraction (Figure 5H), whereas the 
distribution of NBD-PE fluorescence was unchanged both in the presence or absence of 
Mfn2 (Figure S9B).   
In accord with these data, confocal microscopy revealed that Mfn2 (1–613) induced the 
formation of rigid domains containing exclusively NBD-PS (green color) from 
liposomes containing both NBD-PS (green) and Rhodamine-PE (red) (Figure 5I). Lipid 
domains were not generated when Mfn2 (1–613) was exposed to liposomes containing 
NBD-PC and Rhodamine-PE (Figure S9C). Given the unexpected capacity of Mfn2 (1–
613) to generate PS-rich domains in membranes, we evaluated whether this capacity 
showed time-dependence and if it occurred with different types of liposomes. Using a 
well-established fluorescence resonance energy transfer-based membrane assay64,65, we 
incubated control and Mfn2 (1–613) proteins with a mix of donor liposomes (containing 
NBD-phospholipids and Rhodamine-PE) and acceptor liposomes (non-fluorescent). The 
presence of Mfn2 (1–613) induced the release of NBD fluorescence in a time-dependent 
manner in liposomes containing NBD-PS but not NBD-PE (Figures 5J and S9D). 
Similar results were obtained using liposomes containing fluorescent TopFluor 
(TopFluor-PS or TopFluor-PE) derivatives of phospholipids, which are smaller in size 
than NBD-phospholipids (Figures S9E, and S9F). Our results support the view that 
Mfn2 binds PS and has the capacity to isolate it from membranes and to form rigid 
domains enriched in PS. These findings are consistent with a role for Mfn2 in 
exchanging lipids from different membranes or remodeling them in membranes, which 
may be due to lipid rearrangement. 
 
PS-dependent remodeling activity of Mfn2 requires an intact N-terminal region 
To address the specificity of Mfn2 functions, we tested whether Mfn1 has the same 
activities. To evaluate similar protein fragments in Mfn1 and in Mfn2, we expressed a 
recombinant truncated version of Mfn1 (1–592) in E. coli, which was purified under 
identical conditions as for Mfn2 (1–613) (Figure 6A). We first determined whether 
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Mfn1 (1–592) had phospholipid-binding activity. Liposome flotation assays revealed 
that, in contrast to Mfn2 (1–613), Mfn1 bound PC, PE, and PS phospholipids to a 
similar extent (Figure 6B). In a second analysis, lipid extraction assays revealed that 
Mfn1(1–592) failed to extract NBD-PS from liposomes (Figure 6C), but it did extract 
NBD-PE (Figure 6D), pointing to distinct functions for Mfn1 and Mfn2.   
To better understand the basis for the differential capacity of Mfn1 and Mfn2 to bind 
and extract phospholipids, we examined the amino acid sequences of the two proteins 
(Figure 6E). Alignment analysis revealed that the N-terminal (20 aa residues) sequence 
of Mfn2 was absent in Mfn1. We then expressed and purified a mutant form of Mfn2 
lacking this fragment (referred to as Mfn2 21–613) in E.coli (Figure 6F) and used it in 
liposome flotation assays. Results showed that Mfn2 (21–613) bound to PS, PE, PC 
(Figure 6G). Notably, lipid extraction assays revealed that purified Mfn2 (21–613) 
extracted both NBD-PS and NBD-PE from liposomes (Figure 6H and 6I). Thus, the 
Mfn2 (21–613) mutant combines the properties of both Mfn1 and Mfn2, suggesting that 
the N-terminal fragment is key to confer selectivity to extract PS.  
 
Re-expression of Mfn2 in mice on MCD diet alleviates liver disease  
After establishing the unique action of Mfn2 on phospholipid partition and metabolism, 
we next examined the consequences in liver under conditions of reduced Mfn2 
expression during NASH. Specifically, we assessed whether the reduced Mfn2 levels in 
mice on MCD diet was linked to impaired PS transfer and whether it was key to the 
pathological alterations. We also investigated the possible role of ER stress in this 
scenario. Mice were placed on MCD or chow diet for two weeks and were then 
intravenously injected with a control adenovirus or with adenoviruses encoding Mfn2 or 
BIP, and livers were studied one week later. Hepatic Mfn2 expression was normalized 
in MCD mice upon injection of Mfn2 adenoviruses (Figures S10A, and S10C), whereas 
BIP failed to recover Mfn2 levels (Figures S10B and S10C). Compared with the control 
diet, the MCD diet induced an enhanced incorporation of radiolabeled L-Ser into PS, 
and a low synthesis of PE and PC in hepatic MAMs (Figure 7A). Mfn2 re-expression 
normalized the incorporation of L-Ser into PE and PC, whereas BIP did not ameliorate  
as Mfn2 the low levels of phospholipid synthesis (Figure 7A). 
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Analysis of fibrosis in liver sections of MCD diet-fed mice showed that Mfn2-re-
expressing mice had less Sirius red staining than mice treated with control adenovirus 
(Figure 7B), whereas the expression of BIP only partially diminished fibrosis (Figure 
7B). Similarly, triglyceride accumulation in liver was decreased upon Mfn2 re-
expression as assessed by H&E staining (Figure 7B), and by quantification of 
triglycerides (Figure 7C). By contrast, BIP expression failed to normalize hepatic 
triglycerides in MCD diet-fed mice (Figure 7B, and 7C). As expected, the expression of 
inflammatory and fibrosis markers was markedly decreased by Mfn2 re-expression, but 
not by BIP overexpression (Figures 7D). Finally, both BIP and Mfn2 treatments 
normalized all UPR markers upregulated in MCD mice (Figure S10D). 
Overall, our data strongly suggest that Mfn2 repression plays a key role in the 
development of steatosis, inflammation and fibrosis in a mouse model of NASH. 
Moreover, we have identified a defect in phospholipid synthesis in MCD diet-fed mice, 
which it is crucial for the development of the pathology. Our data are consistent with a 
major role of Mfn2 in the normalization of PS transfer from ER to mitochondria, which 








We report that Mfn2 plays a key role in liver homeostasis by controlling both PS 
transfer from ER to mitochondria and the UPR. Accordingly, hepatic ablation of Mfn2 
results in unbalanced phospholipid metabolism, leading to ER stress and triggering liver 
inflammation and fibrosis, which takes place early in the life of these mice and occurs 
even on a normal diet and in the absence of obesity. In addition, mice with liver-specific 
knockout of Mfn2 have enhanced susceptibility to liver cancer with age or in response 
to carcinogenic agents. Supporting the clinical relevance of these findings, we show that 
hepatic Mfn2 expression is lower in patients with NASH than in those with steatosis. 
Mfn2 expression is also repressed in mouse models of steatosis and NASH, and its re-
expression diminishes NASH-like liver pathologies. Taken together, our data indicate 
that hepatic Mfn2 is a key protein to maintain healthy liver function and its repression is 
involved in the development of liver disease.  
 
We show that the UPR caused by Mfn2 deficiency plays a key role in the development 
of hepatic inflammation, apoptosis, compensatory proliferation and fibrosis, which in 
turn contributes to the development of liver cancer48. Thus, normalization of UPR 
response by BIP gain-of-function restores inflammation to control levels and reduces 
apoptosis, hyper-proliferation and fibrosis, which would prevent the development of 
cancer. These results are consistent with our previous observations that deficient hepatic 
insulin signaling is normalized in Mfn2 knockout mice treated with 
tauroursodeoxycholic acid31. Indeed, chronic ER stress plays a key role in the 
pathophysiology associated with Mfn2 deficiency, and appears to be responsible for the 
alterations in mitochondrial metabolism that have been detected in Mfn2-deficient 
cells29. The fact that inflammation, fibrosis and insulin resistance are modulated by ER 
stress may explain the relationship reported between steatosis, insulin resistance, and 
NASH48,52,66-68. 
 
We found that Mfn2 re-expression normalizes liver function in a mouse model of 
NASH, whereas BIP expression only partially counters steatosis, inflammation and 
fibrosis. These findings indicate that whereas Mfn2 likely plays a key role in the 
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development of liver disease in murine NASH, the UPR is a secondary contributing 
factor.  
 
Our data also reveal that Mfn2 deficiency markedly impairs phospholipid metabolism 
and this lies upstream of the UPR. Thus, BIP-induced amelioration of UPR failed to 
normalize lipid metabolism. The changes in phospholipid metabolism associated with 
Mfn2 deficiency were characterized by lower rates of synthesis of PS, PE and PC, 
reduced expression of phosphatidylserine synthases PSS1 and PSS2, and reduced 
abundance of PSS1 in MAM fractions. We also found that a reduction in hepatic 
phospholipid metabolism explains the enhanced accumulation of triglycerides, the UPR 
and inflammation. While the re-expression of PSS1 was not sufficient to mitigate the 
defective synthesis of PE and PC in Mfn2-depleted livers, it significantly reduced 
hepatic triglycerides, revealing a close regulation of phospholipid and triglyceride 
synthesis in MAMs. Expression of both full-length and truncated Mfn2, lacking the 
transmembrane domains, improved phospholipid metabolism in Mfn2-deficient livers. 
Thus, our results indicate that loss of hepatic Mfn2 expression changes phospholipid 
metabolism by altering two different steps: 1) reducing the transfer of PS from the ER 
to mitochondria, and 2) inhibiting PS synthesis as a consequence of a compensatory 
reduced expression of PPS1 and PSS2. 
 
Importantly, we describe a new molecular function of Mfn2 in the maintenance of 
hepatic phospholipid metabolism. Mfn2 has the capacity to bind PS in vitro, and to 
cause partitions of PS into rigid membrane domains. These activities are specific for PS 
and are not found with other phospholipids such as PE or PC.  Indeed, these data may 
be key to understand the molecular basis for the multiple cellular effects of 
Mfn226,31,32,69. In addition, our observations provide molecular insights into the steps 
involved in the transfer of PS from ER to mitochondria. We propose that Mfn2 
participates in the generation of PS-enriched domains at the ER-mitochondria contact 
sites and they favor the activity of potential PS transport proteins such as the oxysterol-
binding protein (OSBP)-related proteins ORPs (ORP5/ORP8) or VAT-1. ORP5/8 binds 
PS in vitro70 and mediates PI4P/PS counter transport between the ER and the plasma 
membrane71.  These proteins have also been identified in MAMs72 and therefore may 




The observation of a link between Mfn2 and phospholipids is highly relevant because of 
their influence on membrane-dependent cellular functions, antioxidant, anti-
inflammatory, anti-fibrotic properties, and cellular signaling73,74. Thus, obesity has been 
reported to increase the hepatic PC/PE ratio which inhibits SERCA activity75. In 
addition, genetic inhibition of PEMT, which catalyzes the conversion of PE to PC, 
relieves ER stress and improves systemic glucose homeostasis in obesity75,76. Mfn2 
levels are increased in MAMs in obese mice56 under conditions in which enhanced PC 
production has been reported75. Furthermore, low levels of phospholipids in bile due to 
the disruption of membrane transporters are linked to liver disease77,78. Another 
important feature of our work is the observation that hepatic Mfn2 ablation provokes 
MAM remodeling similar to that detected in HFD or genetic obesity. This is also 
relevant because remodeling of MAM interactions in liver in obesity has been shown to 
result in undesirable side effects such as triacylglycerol accumulation and insulin 
resistance56. Specifically, hepatic MAM shows an enhanced abundance of protein 
markers such as PACS2, IP3R1, and IP3R2 during obesity56, which is consistent with 
the pattern of changes detected in Mfn2-deficient livers. Accordingly, we propose that 
alterations in Mfn2 expression have an impact on MAM reorganization, perhaps 
through changes in the phospholipid composition in ER-mitochondrial contact sites. 
These observations also reveal that changes to Mfn2 levels may alter the composition of 
tethers at ER-mitochondrial contact sites, and this may be dependent on the cell context. 
In addition, those data complement the observations that disruption of individual MAM 
components seem to be sufficient to alter phospholipid synthesis in disorders such as 
Alzheimer disease and Lenz-Majewski syndrome79-81.   
 
In contrast to the function of Mfn2, Mfn1 shows a broader phospholipid binding activity 
but it does not generate PE- or PC-rich domains. The N-terminal region (20 amino acid 
residues) of Mfn2 (not present in Mfn1) is key for PS specificity, as elimination of this 
region generates a mutant form of Mfn2 incorporating the capacities of Mfn1 and Mfn2, 
indicating a hybrid behavior. Further studies will be needed to understand the molecular 
basis for the PS binding and extraction activities of Mfn2.  
 
In conclusion, our data support the view that Mfn2 sustains PS transfer to the 
mitochondria for conversion to PE. The effects on phospholipid metabolism may 
explain the role of Mfn2 in the maintenance of MAMs and proper lipid metabolism and 
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ER homeostasis. Thus, we propose Mfn2 as a potential therapeutic target for 
counteracting the development of liver disease related to NASH and liver cancer.  
 
Experimental Procedures. 
Experimental Procedures see Supplemental Information.  
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FIGURE 1.  Mfn2 is reduced in NASH and liver-specific Mfn2 ablation in mice 
causes a NASH-like phenotype. A) Quantification of Mfn2 protein in liver biopsies 
from steatotic (NAS ≤3, n=7) and NASH (NAS ≥5, n=8) patients. B) Quantification of 
Mfn2 protein in liver from mice on chow diet (C) or high-fat diet (HFD) as a model of 
steatosis (n=4 mice per group). C) Representative H&E and Sirius red staining images 
in liver sections from 8-week-old C57Bl6/J mice fed either a chow diet (C) or a 
methionine/choline-deficient diet combined with HFD and supplemented with 0.1% L-
methionine in drinking water (MCD) (scale bar, 200 m). D) Triglyceride (TAG) levels 
in liver from mice on C and MCD diets (n=5 mice per group). E) Quantification of 
Mfn2 protein in liver from C (n=5) and MCD mice (n=4). F) Hepatic pro-inflammatory 
factors in control (C) and liver-specific Mfn2 KO (L-KO) mice measured by ELISA 
(n=8 mice per group). G) Hepatic TAG levels in C and L-KO mice (n=8–12 mice per 
group). H) Oleate incorporation into different lipid species in hepatocytes isolated from 
C and L-KO mice (n=4 mice per group, each experiment performed in triplicate). I) 
Representative Sirius red staining and TEM images in liver sections from 27-week-old 
C and L-KO mice fed a normal diet (scale bars, 200 m in Sirius Red staining images, 
and 5 m in TEM images). J) Hepatic expression of genes involved in collagen 
synthesis in C and L-KO mice (n=5 mice per group). K) Representative macroscopic 
images of liver from 24 month-old C and L-KO mice fed a normal diet, and 
quantification of liver tumors expressed as the mean of number of tumours in livers 
from 5 mice. In panel A, data are expressed as mean ± SD, and in the remaining panels 
as mean ± SE.  *p<0.05 vs.  control group in each case.  
 
FIGURE 2. Normalization of ER stress ameliorates inflammation and fibrosis but 
not lipid metabolism in L-KO mice. Control (C) mice were studied 5 days after tail 
vein injection of control LacZ adenoviruses (C+AdC) and L-KO mice were studied 5 
days after tail vein injection of control (LacZ) (L-KO+AdC, red bars) or BIP 
adenoviruses (L-KO+AdBIP, yellow bars) (n=4 mice per group). Data are expressed as 
values relative to control LacZ group (shown as a discontinuous line). A) 
Representative western blot of protein expression of hepatic ER stress markers. B) 
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Hepatic pro-inflammatory factors measured by ELISA. C) Plasma levels of IL-1. D) 
Expression of genes involved in collagen synthesis. E) Hepatic TAG levels . F) Oleate 
incorporation into lipid species in isolated hepatocytes. Data are expressed as mean ± 
SE. Statistical analysis was performed by using one-way ANOVA followed by post-hoc 
t tests. *p<0.05 L-KO vs. C mice, $p<0.05 L-KO+AdBIP vs. L-KO+AdC mice.  
 
FIGURE 3. Mfn2 ablation alters hepatic phospholipid metabolism independently 
of ER stress. A) Hepatic phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
content measured by lipidomics in control (C) (n=11) and L-KO (n=13) mice. Data are 
expressed as fold-change vs. C mice. Significant compounds are shown in the heatmap 
(p<0.05) out of 128 phospholipids analyzed. B) Graphical scheme of phosphatidylserine 
(PS), phosphatidylethanolamine (PE) and PS synthesis in mitochondria-associated ER 
membranes (MAMs). C–E) 3H- L-serine incorporation into PS (C), PE (D), and 
phosphatidylcholine (PC) (E) in hepatic mitochondria-associated ER-enriched fractions 
from C and L-KO mice (n=5–7 mice per group). F) 3H- L-serine incorporation into PS, 
PE and PC in hepatic mitochondria-associated ER-enriched fractions from control (lacZ 
injected, C+AdC), L-KO (lacZ injected, L-KO+AdC, red bars), and L-KO (BIP 
injected, L-KO+BIP mice, yellow bars) (n=4 mice per group). Data are expressed as 
values relative to C+AdC group (shown as a discontinuous line). G) 3H-L-serine 
incorporation into PS, PE and PC in hepatic mitochondria-associated ER-enriched 
fractions from C+AdC, L-KO+AdC (red bars), and L-KO (Mfn2 injected, L-
KO+AdMfn2 mice, grey bars) (n=4 mice per group). Data are expressed as values 
relative to C+AdC group (shown as a discontinuous line). H) Representative western 
blot showing hepatic expression of PSS1, PSS2 and PEMT proteins levels in 8-week-
old C and L-KO mice (n=4 mice per group). I) Protein expression of MAM proteins in 
liver from C and L-KO mice (n=4 mice per group). Data are expressed as mean ± SE. 
Statistical analysis was performed by using one-way ANOVA followed by post-hoc t 
tests.   *p<0.05 L–KO vs. C mice, $p<0.05 vs. L-KO+AdC mice.  
 
FIGURE 4.  Deficiency of hepatic phosphatidylserine synthase 1 and 2 phenocopies 
Mfn2 ablation. A) Quantification of hepatic protein expression of PSS1 and PSS2 5 
days after tail vein injection with control LacZ (C) or Ptdss1/Ptdss2 (KD) siRNA 
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adenoviruses (n=5 mice per group). B) Quantification of PSS1 protein in MAM 
fractions obtained from C or KD mice (n=5 mice per group). C) 3H-L-serine 
incorporation into PS and PE in hepatic mitochondria-associated ER-enriched fractions 
from C or KD mice (n=4 mice per group). D) Hepatic triglyceride (TAG) levels in C 
and KD mice (n=4 mice per group). E) Quantification of protein expression of hepatic 
ER stress markers in C and KD mice (n=4 mice per group). F) Hepatic expression of 
genes involved in inflammation in C and KD mice (n=5 mice per group). G) 
Quantification of Mfn2 protein in MAM fractions from C and KD mice. H) Scheme of 
PSS1 overexpression in mice. I) mRNA levels of Ptdss1 and Ptdss2 from control (lacZ 
injected, C+AdC), L-KO (lacZ injected, L-KO+AdC, red bars), and L-KO (Ptdss1 
injected, L-KO+Ptdss1, blue bars) mice (n=3–5 mice per group). J) 3H-L-serine 
incorporation into PS, PE and PC in hepatic mitochondria-associated ER-enriched 
fractions from C+AdC, L-KO+AdC (red bars), and L-KO+Ptdss1 mice (blue bars) 
(n=3–5 mice per group). K) Hepatic TAG levels in C+AdC, L-KO+AdC (red bars), and 
L-KO+Ptdss1 (blue bars) mice. L) Quantification of protein expression of hepatic ER 
stress markers in C+AdC, L-KO+AdC (red bars), and L-KO+Ptdss1 (blue bars) mice 
(n=3–5 mice per group). Data are expressed as values relative to C+AdC group (shown 
as a discontinuous line). Data are expressed as mean ± SE. Statistical analysis was 
performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs. C mice, 
$p<0.05 vs. L-KO+AdC mice. 
 
FIGURE 5. Mfn2 binds phosphatidylserine and generates phosphatidylserine-rich 
domains in membranes. A) Binding of Mfn2 protein immunoprecipitated from liver to 
different phospholipids on a Membrane Lipid StripTM. B) Binding of a truncated form 
of Mfn2 (1–613), expressed in liver and purified by affinity chromatography, to 
phospholipids on a Membrane Lipid StripTM. C) 3H-L-serine incorporation into PS, PE 
and PC in hepatic mitochondria-associated ER-enriched fractions from mice injected 
with LacZ in control (C+AdC) and L-KO (L-KO+AdC, red bars) mice and with a Mfn2 
(1–613) adenovirus (L-KO+Mfn2 (1–613), blue bars) (n=4 mice per group). Data are 
expressed as values relative to the C+AdC group (shown as a discontinuous line). D) 
Representative Commassie-stained gel of the purification of Mfn2 (1–613) expressed in 
E. coli. E) Binding of Mfn2 (1–613) expressed in E. coli to different phospholipids on a 
Membrane Lipid StripTM. F) Representative western blot against Mfn2 after the 
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liposome flotation assay with different fluorescent (NBD) phospholipids. G) Scheme of 
the NBD-Phospholipid liposome extraction assay. H) Quantification of NBD-PS 
liposome extraction assay with Mfn2 (1–613) expressed in E. coli (n=6). I) Confocal 
microscopy images of liposomes in the absence or presence of Mfn2 (1–613), showing 
the formation of the NBD-PS rigid domain with Mfn2 (1–613). J) Kinetic FRET assay 
with NBD-PS and Rhod-PE to evaluate the capacity of Mfn2 (1–613) to dequench 
NBD-PS fluorescence from liposomes (n=6). Data are expressed as mean ± SE. 
Statistical analysis in panel H: *p<0.05 vs.  C $p<0.05 vs. L-KO+AdC. Statistical 
analysis in panel J was performed by using a two-way ANOVA (*p<0.0001). 
 
FIGURE 6. Phosphatidylserine binding and extraction activities of Mfn2 require 
an intact N-terminal region. A) Representative Commassie-stained gel of the 
purification of a short form of Mfn1 (1–592) expressed in E. coli. B) Representative 
western blot against histidine showing Mfn1 protein after the liposome flotation assay 
with different non-fluorescent phospholipids. C) Quantification of NBD-PS liposome 
extraction assay with Mfn1 (1–592) expressed in E. coli (n=3). D) Quantification of 
NBD-PE extraction assay with Mfn1 (1–592) expressed in E. coli (n=3). E) Mfn2 and 
Mfn1 human sequence alignment. F) Representative Commassie-stained gel of 
purification of Mfn2 (21–613) expressed in E. coli. G) Representative western blot 
against histidine showing Mfn2 (21–613) protein after the liposome flotation assay with 
non-fluorescent phospholipids. H) Quantification of NBD-PS liposome extraction assay 
with Mfn2 (21–613) expressed in E. coli (n=3). I) Quantification of NBD-PE liposome 
extraction assay with Mfn2 (21–613) expressed in E. coli (n=3). Data are expressed as 
mean ± SE. *p<0.05 vs. C. 
 
FIGURE 7. Mfn2 re-expression improves the NASH phenotype in mice. A) 3H-L-
serine incorporation into PS, PE and PC in hepatic mitochondria-associated ER-
enriched fractions from control mice injected with AdC (null adenovirus) (C+AdC, 
white bars), MCD mice injected with AdC (MCD+AdC, blue bars), with AdMfn2 
(MCD+AdMfn2, red bars) or with AdBIP (MCD+BIP, yellow bars) (n=4 mice per 
group). B) Representative H&E and Sirius red staining images in liver sections from 
C+AdC, MCD+AdC, MCD+Mfn2 and MCD+BIP mice (scale bar, 200 m). C) Hepatic 
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triglyceride (TAG) levels in C+AdC (white bars), MCD+AdC (blue bars), MCD+Mfn2 
(red bars) and MCD+BIP (yellow bars) mice (n=4 mice per group). D) Hepatic pro-
inflammatory factors and genes involved in collagen synthesis in C+AdC (white bars), 
MCD+AdC (blue bars), MCD+Mfn2 (red bars) and MCD+BIP (yellow bars) mice (n=4 
mice per group). Data are expressed as the mean ± SE. Statistical analysis was 
performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs.  
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